文献速递胸部肿瘤

MRTX-500二期试验:西曲替尼联合纳武利尤单抗用于经检查点抑制剂或化疗后进展的非鳞状非小细胞肺癌患者

MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.
PubMed 文献 · J Thorac Oncol · 2023-02-24

MRTX-500二期研究评估西曲替尼(120 mg每日)联合纳武利尤单抗(每2或4周)治疗经检查点抑制剂或化疗后进展的晚期非鳞状非小细胞肺癌。124例经检查点抑制剂治疗患者(无既往临床获益35例,有既往临床获益89例)和32例未接受检查点抑制剂患者接受治疗。研究者评估的客观缓解率在无既往临床获益组为11.4%,有既往临床获益组为16.9%,未接受检查点抑制剂组为25.0%。

要点

  • 经检查点抑制剂治疗无既往临床获益组客观缓解率11.4%,有既往临床获益组16.9%,未接受检查点抑制剂组25.0%。
  • 中位无进展生存期在无既往临床获益、有既往临床获益和未接受检查点抑制剂组分别为3.7、5.6和7.1个月。
  • 总体(N=156)任何级别治疗相关不良事件发生率为93.6%,3/4级为58.3%,1例未接受检查点抑制剂患者发生5级治疗相关不良事件。

核心结论

  • 西曲替尼联合纳武利尤单抗安全性可控,虽未达到客观缓解率主要终点,但在经检查点抑制剂治疗的非鳞状非小细胞肺癌患者中显示出抗肿瘤活性和令人鼓舞的生存获益。

研究设计与样本

  • 二期MRTX-500研究,评估西曲替尼(120 mg每日)联合纳武利尤单抗(每2或4周)治疗经检查点抑制剂或化疗后进展的晚期非鳞状非小细胞肺癌患者。
  • 经检查点抑制剂治疗患者分为无既往临床获益(NPCB,n=35)和有既往临床获益(PCB,n=89)两组,未接受检查点抑制剂患者32例接受治疗。
  • 主要终点为客观缓解率(ORR),次要目标包括安全性和次要疗效终点。

主要发现

  • 研究者评估的客观缓解率在无既往临床获益组为11.4%,有既往临床获益组为16.9%,未接受检查点抑制剂组为25.0%。
  • 中位无进展生存期在无既往临床获益、有既往临床获益和未接受检查点抑制剂组分别为3.7、5.6和7.1个月。
  • 中位总生存期在无既往临床获益组为7.9个月,有既往临床获益组为13.6个月,未接受检查点抑制剂组未达到(中位随访20.4个月)。
  • 总体(N=156)任何级别治疗相关不良事件发生率为93.6%,3/4级为58.3%,1例未接受检查点抑制剂患者发生5级治疗相关不良事件。
  • 治疗相关不良事件导致14.1%的患者停药,42.9%的患者剂量减少或中断;生物标志物分析支持免疫刺激作用机制。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Sitravatinib, a receptor tyrosine kinase inhibitor targeting TYRO3, AXL, MERTK receptors, and vascular epithelial growth factor receptor 2, can shift the tumor microenvironment toward an immunostimulatory state. Combining sitravatinib with checkpoint inhibitors (CPIs) may augment antitumor activity. METHODS: The phase 2 MRTX-500 study evaluated sitravatinib (120 mg daily) with nivolumab (every 2 or 4 wk) in patients with advanced nonsquamous NSCLC who progressed on or after previous CPI (CPI-experienced) or chemotherapy (CPI-naive). CPI-experienced patients had a previous clinical benefit (PCB) (complete response, partial response, or stable disease for at least 12 weeks then disease progression) or no PCB (NPCB) from CPI. The primary end point was objective response rate (ORR); secondary objectives included safety and secondary efficacy end points. RESULTS: Overall, 124 CPI-experienced (NPCB, n = 35; PCB, n = 89) and 32 CPI-naive patients were treated. Investigator-assessed ORR was 11.4% in patients with NPCB, 16.9% with PCB, and 25.0% in CPI-naive. The median progression-free survival was 3.7, 5.6, and 7.1 months with NPCB, PCB, and CPI-naive, respectively; the median overall survival was 7.9 and 13.6 months with NPCB and PCB, respectively (not reached in CPI-naive patients; median follow-up 20.4 mo). Overall, (N = 156), any grade treatment-related adverse events (TRAEs) occurred in 93.6%; grade 3/4 in 58.3%. One grade 5 TRAE occurred in a CPI-naive patient. TRAEs led to treatment discontinuation in 14.1% and dose reduction or interruption in 42.9%. Biomarker analyses supported an immunostimulatory mechanism of action. CONCLUSIONS: Sitravatinib with nivolumab had a manageable safety profile. Although ORR was not met, this combination exhibited antitumor activity and encouraged survival in CPI-experienced patients with nonsquamous NSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. He K, Berz D, Gadgeel SM, et al. MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. J Thorac Oncol. 2023. PMID: 36842467. doi:10.1016/j.jtho.2023.02.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。